Published in Vaccine on July 23, 2011
Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis (2012) 1.28
Transcriptional profiling of human dendritic cell populations and models--unique profiles of in vitro dendritic cells and implications on functionality and applicability. PLoS One (2013) 1.05
Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology (2012) 0.99
Dendritic cell based vaccines for HIV infection: the way ahead. Hum Vaccin Immunother (2013) 0.95
Human dendritic cell subsets in vaccination. Curr Opin Immunol (2013) 0.93
HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. J Virol (2015) 0.86
Regulatory T cells in HIV infection: can immunotherapy regulate the regulator? Clin Dev Immunol (2012) 0.85
Immune Suppression by Myeloid Cells in HIV Infection: New Targets for Immunotherapy. Open AIDS J (2014) 0.83
Lost therapeutic potential of monocyte-derived dendritic cells through lost tissue homing: stable restoration of gut specificity with retinoic acid. Clin Exp Immunol (2013) 0.83
Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. J Virol (2012) 0.83
Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes. Cell Mol Immunol (2014) 0.82
Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity. PLoS Pathog (2015) 0.81
Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine. PLoS One (2012) 0.80
Exome analysis of HIV patients submitted to dendritic cells therapeutic vaccine reveals an association of CNOT1 gene with response to the treatment. J Int AIDS Soc (2014) 0.80
Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant. PLoS One (2013) 0.78
Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway. Cell Mol Immunol (2016) 0.78
Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individuals. PLoS One (2013) 0.77
Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1. Hum Vaccin Immunother (2013) 0.77
Differential inflammasome expression and IL-1β secretion in monocyte-derived dendritic cells differentiated with IL-4 or IFN-α. AIDS Res Ther (2013) 0.76
Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals. PLoS One (2013) 0.75
Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis. Int J Mol Sci (2016) 0.75
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med (2003) 4.53
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med (2010) 3.81
HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity (2004) 2.86
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol (2009) 2.51
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med (2008) 1.85
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol (2002) 1.84
Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol (2009) 1.79
Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS (2008) 1.63
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (2004) 1.61
Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J Exp Med (2011) 1.60
Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J Immunol (2009) 1.52
A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS (2008) 1.47
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr (2009) 1.46
Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin β7. J Immunol (2011) 1.31
CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog (2012) 1.28
Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest (2011) 1.27
Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood (2013) 1.24
Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol (2005) 1.23
HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology (2014) 1.22
CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol (2011) 1.21
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr (2004) 1.19
The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells. J Immunol (2007) 1.18
Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J Immunol (2005) 1.15
Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol (2013) 1.14
Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J Virol (2011) 1.14
Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection. Blood (2007) 1.13
CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS (2014) 1.11
A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS (2011) 1.10
Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. PLoS Pathog (2013) 1.10
Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. J Med Virol (2002) 1.10
Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One (2013) 1.08
Decreased levels of circulating IL-21 in HIV-infected AIDS patients: correlation with CD4+ T-cell counts. Viral Immunol (2008) 1.07
A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses. J Immunol Methods (2006) 1.04
Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood (2012) 1.03
HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. J Infect Dis (2009) 1.02
Immunophenotypic patterns of CD8+ T cell subsets expressing CD8alphaalpha and IL-7Ralpha in viremic, aviremic and slow progressor HIV-1-infected subjects. Clin Immunol (2007) 0.99
Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression. Clin Immunol (2007) 0.98
Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation. J Immunol (2011) 0.98
Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data. AIDS (2011) 0.96
Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol (2009) 0.93
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol (2004) 0.93
IL-21 enhances NK cell functions and survival in healthy and HIV-infected patients with minimal stimulation of viral replication. J Leukoc Biol (2010) 0.93
HIV Gag p24 specific responses secreting IFN-gamma and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load. Clin Immunol (2009) 0.91
Altruism motivates participation in a therapeutic HIV vaccine trial (CTN 173). AIDS Care (2010) 0.91
HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication. J Infect Dis (2010) 0.91
Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection. J Infect Dis (2002) 0.90
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS (2008) 0.89
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS (2005) 0.89
The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection. AIDS (2016) 0.89
The colocalization potential of HIV-specific CD8+ and CD4+ T-cells is mediated by integrin β7 but not CCR6 and regulated by retinoic acid. PLoS One (2012) 0.88
Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age. J Acquir Immune Defic Syndr (2002) 0.88
The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. Cancer Res (2009) 0.88
Mind the gap: lack of association between KIR3DL1*004/HLA‐Bw4-induced natural killer cell function and protection from HIV infection. J Infect Dis (2010) 0.88
Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. HIV Clin Trials (2005) 0.87
Potential role of IL-18 in the immunopathogenesis of AIDS, HIV-associated lipodystrophy and related clinical conditions. Curr HIV Res (2010) 0.87
Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Trials (2003) 0.86
Role of interleukin-18 in the development and pathogenesis of AIDS. AIDS Rev (2009) 0.86
The PKR activator, PACT, becomes a PKR inhibitor during HIV-1 replication. Retrovirology (2013) 0.86
Persistence of high levels of blood soluble human leukocyte antigen-G is associated with rapid progression of HIV infection. AIDS (2009) 0.85
Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects. Antivir Chem Chemother (2004) 0.85
Transcriptional profiling reveals molecular signatures associated with HIV permissiveness in Th1Th17 cells and identifies peroxisome proliferator-activated receptor gamma as an intrinsic negative regulator of viral replication. Retrovirology (2013) 0.85
Regulatory T cells in HIV infection: can immunotherapy regulate the regulator? Clin Dev Immunol (2012) 0.85
Changes in function of HIV-specific T-cell responses with increasing time from infection. Viral Immunol (2010) 0.85
T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers. AIDS Res Ther (2011) 0.84
siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals. J Clin Immunol (2009) 0.83
The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90. PLoS One (2009) 0.82
Identifying the early post-HIV antibody seroconversion period. J Infect Dis (2011) 0.82
Long-term immunosuppression with anti-CD25 monoclonal antibodies in heart transplant patients with chronic kidney disease. J Heart Lung Transplant (2009) 0.82
Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. AIDS (2011) 0.82
Assessment of longitudinal changes in HIV-specific effector activity in subjects undergoing untreated primary HIV infection. AIDS (2004) 0.82
Drug resistance mutations and the cellular immune response: a valuable synergy for the development of novel immune therapies. Curr Opin HIV AIDS (2007) 0.82
Elevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+ Patients: Correlations With Known Markers of Disease Progression. J Acquir Immune Defic Syndr (2015) 0.81
Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada. AIDS Res Hum Retroviruses (2008) 0.81
Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J Virol (2009) 0.81
Temporal effect of HLA-B*57 on viral control during primary HIV-1 infection. Retrovirology (2013) 0.81
Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy. AIDS Res Hum Retroviruses (2012) 0.81
Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee. Can J Infect Dis Med Microbiol (2011) 0.80
Autologous HIV-1 clade-B Nef peptides elicit increased frequency, breadth and function of CD8+ T-cells compared to consensus peptides. PLoS One (2012) 0.80
Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am J Hematol (2008) 0.80
Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. Vaccine (2010) 0.80
Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults. AIDS (2016) 0.79
Down-regulation of CTLA-4 by HIV-1 Nef protein. PLoS One (2013) 0.79
HHV-8 linked to Kaposi's sarcoma, Castleman's disease and primary effusion lymphoma in a HIV-1-infected man. J Clin Virol (2008) 0.79
Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports. Medicine (Baltimore) (2017) 0.78
Relative contribution of HIV-specific functional lymphocyte subsets restricted by protective and non-protective HLA alleles. Viral Immunol (2011) 0.78
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS (2006) 0.78
HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing. J Leukoc Biol (2005) 0.78
Predictive value of interleukin-7 levels for virological response to treatment in HIV-1-infected children. Viral Immunol (2007) 0.77
French HIV experts on early antiretroviral treatment for prevention: uncertainty and heterogeneity. J Int Assoc Provid AIDS Care (2014) 0.77
Influence of Hepatitis C Virus Sustained Virological Response on Immunosuppressive Tryptophan Catabolism in ART-Treated HIV/HCV Coinfected Patients. J Acquir Immune Defic Syndr (2016) 0.77